Handbook of Clinical medicine

prescribed for terminally ill patients. Severity assessment in COPD Severity assessment has implications for therapy and prognosis. The BODE index (Body mass index, airfl ow Obstruction, Dyspnoea and Exercise capacity) helps predict outcome and number and severity of exacerbations. The Global Initia- tive for COPD (GOLD) categorizes severity of COPD into four stages (mild, moderate, severe, and very severe) based on post-bronchodilator FEV1% predicted, but it is not useful for predicting total mortality for 3 years of follow-up and onwards.42 __OOHHCCMM__1100ee..iinnddbb 118844 0022//0055//22001177 1199::0077 enicidem tsehC British Thoracic Society (BTS)/NICE COPD guidelines 185 More advanced COPD Management of COPD Initiate short-acting 2-antagonist (SABA)/ short-acting muscarinic antagonist (SAMA) FEV1 >50% FEV1 <50% Long-acting Long-acting muscarinic LABA plus inhaled 2-antagonist (LABA) antagonist (LAMA)*,4 corticosteroid (ICS) in combined inhaler LABA plus inhaled LAMA plus LABA/ICS corticosteroid (ICS) combination inhaler Fig 4.14 Management of COPD in primary and secondary care. *Tiotropium (LAMA) is more eff ective than salmeterol in preventing exacerbations for patients with moderate-to-very-severe COPD.43 © National Institute for Health and Clinical Excellence 2010. CG101 Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available from . NICE guidance is prepared for the National Health Service in England. All NICE guidance is
